.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Deloitte
Novartis
Colorcon
AstraZeneca
UBS
Julphar
Baxter
Fish and Richardson
Teva

Generated: November 18, 2017

DrugPatentWatch Database Preview

ELELYSO Drug Profile

« Back to Dashboard

What is the patent landscape for Elelyso, and when can generic versions of Elelyso launch?

Elelyso is a drug marketed by Pfizer and is included in one NDA. There are three patents protecting this drug.

This drug has seventy-eight patent family members in twenty-five countries.

The generic ingredient in ELELYSO is taliglucerase alfa. One supplier is listed for this compound. Additional details are available on the taliglucerase alfa profile page.

Summary for ELELYSO

US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 1
Drug Prices:see details
DailyMed Link:ELELYSO at DailyMed

Pharmacology for ELELYSO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ELELYSO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,391,638 Cell/tissue culturing device and method► Subscribe
9,220,737Plant cell culture expressing human lysosomal proteins and uses thereof► Subscribe
8,449,876Human lysosomal proteins from plant cell culture► Subscribe
7,951,557Human lysosomal proteins from plant cell culture► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ELELYSO

Country Document Number Estimated Expiration
South Korea20120093964► Subscribe
Czech Republic298148► Subscribe
Hungary9904529► Subscribe
South Korea20070022234► Subscribe
Israel171561► Subscribe
Denmark0938544► Subscribe
European Patent Office1618177► Subscribe
BrazilPI0410520► Subscribe
Japan2010525806► Subscribe
Denmark2333083► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Citi
Argus Health
Daiichi Sankyo
Farmers Insurance
Harvard Business School
Merck
Fuji
QuintilesIMS
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot